Current Heart Failure Reports

, Volume 11, Issue 3, pp 337–346

Comorbidity of Heart Failure and Chronic Obstructive Pulmonary Disease: More than Coincidence

Comorbidities of Heart Failure (CE Angermann, Section Editor)


Heart failure and COPD are very common in the elderly. As both syndromes share common risk factors, such as tobacco smoking, and pathophysiological pathways, including systemic inflammation and activation of the neurohumoral system, they frequently coincide. Because of the similar clinical presentation, diagnoses of COPD in the presence of heart failure may be difficult. If spirometry is performed, caution should be taken in the interpretation of the data, as heart failure by itself (in the absence of true COPD) may exert restrictive as well as obstructive alterations in pulmonary function testing. Once COPD is established, concurrent heart failure may impact on the accurate management of these patients as severity grading of COPD could easily be overrated, and thus there is a risk of overuse of pulmonary medication, with the risk of causing cardiac side-effects. The present review focuses on the pathophysiological interrelation of comorbid COPD and heart failure, and provides practical help on how to deal with both diseases in daily practice.


Heart failure COPD Diagnosis Pathophysiology Management Treatment 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med. 1995;333(23):1547–53.PubMedGoogle Scholar
  2. 2.
    Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through clinical examination. J Gen Intern Med. 1993;8(7):383–92.PubMedGoogle Scholar
  3. 3.
    Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One. 2013;8(3):e59225.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012;14(7):718–29.PubMedGoogle Scholar
  5. 5.
    van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135(2):368–77.PubMedGoogle Scholar
  6. 6.
    Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–94.PubMedGoogle Scholar
  7. 7.
    Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264(4):361–9.PubMedGoogle Scholar
  8. 8.
    Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9.PubMedCentralPubMedGoogle Scholar
  9. 9.••
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. Guidelines on heart failure. Also mentioning COPD as an important comorbidity.PubMedGoogle Scholar
  10. 10.
    Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50.PubMedGoogle Scholar
  11. 11.
    Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.PubMedGoogle Scholar
  12. 12.
    Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–12.PubMedGoogle Scholar
  13. 13.
    Kachel RG. Left ventricular function in chronic obstructive pulmonary disease. Chest. 1978;74(3):286–90.PubMedGoogle Scholar
  14. 14.
    Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20–2.PubMedGoogle Scholar
  15. 15.
    McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med Off J Soc Acad Emerg Med. 2003;10(3):198–204.Google Scholar
  16. 16.
    Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006;8(7):706–11.PubMedGoogle Scholar
  17. 17.
    Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedGoogle Scholar
  18. 18.
    van Dijk WD, Gupta N, Tan WC, Bourbeau J. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD. 2013;11(1):113–20.PubMedGoogle Scholar
  19. 19.
    Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.PubMedGoogle Scholar
  20. 20.
    Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268–73.PubMedGoogle Scholar
  21. 21.
    Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not <70 %. Chest. 2007;131(2):349–55.PubMedGoogle Scholar
  22. 22.
    Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.PubMedGoogle Scholar
  23. 23.
    Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC, et al. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol Off J German Cardiac Soc. 2012;101(8):637–45.Google Scholar
  24. 24.
    Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, et al. COPD in chronic heart failure: Less common than previously thought? Heart Lung. 2013;42(5):365–71.PubMedGoogle Scholar
  25. 25.
    Olofson J, Bake B, Tengelin MN, Houltz B. COPD 'diagnosis' based on spirometric reference equations. Clin Respir J. 2008;2(4):214–9.PubMedGoogle Scholar
  26. 26.•
    Marks GB. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax. 2012;67(1):85–7. Article discussing critically the LLN definition for diagnosing COPD.PubMedGoogle Scholar
  27. 27.
    Wollmer P, Engstrom G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: An outcome study. Respir Med. 2013;107(9):1460–2.PubMedGoogle Scholar
  28. 28.•
    Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res. 2012;13(1):13. Study showing that hyperinflation is useful to improve the diagnosis of COPD.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–51.PubMedGoogle Scholar
  30. 30.
    Moons KG, Grobbee DE. When should we remain blind and when should our eyes remain open in diagnostic studies? J Clin Epidemiol. 2002;55(7):633–6.PubMedGoogle Scholar
  31. 31.
    Jorge S, Becquemin MH, Delerme S, Bennaceur M, Isnard R, Achkar R, et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc Disord. 2007;7:16.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Assayag P, Benamer H, Aubry P, de Picciotto C, Brochet E, Besse S, et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol. 1998;82(4):459–64.PubMedGoogle Scholar
  33. 33.
    West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet. 1992;340(8822):762–7.PubMedGoogle Scholar
  34. 34.
    Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16(6):461–74.PubMedGoogle Scholar
  35. 35.
    Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18(8):637–44.PubMedGoogle Scholar
  36. 36.
    Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol. 1994;44(1):1–8.PubMedGoogle Scholar
  37. 37.
    Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92(12):1321–5.PubMedGoogle Scholar
  38. 38.
    Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999;99(9):1190–6.PubMedGoogle Scholar
  39. 39.
    Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143(3):429–33.PubMedGoogle Scholar
  40. 40.
    Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol. 1987;17(2):207–9.PubMedGoogle Scholar
  41. 41.
    Kee K, Naughton MT. Heart failure and the lung. Circ J Off J Jpn Circ Soc. 2010;74(12):2507–16.Google Scholar
  42. 42.••
    Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart failure - COPD or congestion? Int J Cardiol 2013. Study that assessed serial spirometry measurements in patients hospitalized for acute decompensated systolic heart failure. It showed that COPD would be overdiagnosed when based on spirometry at the end of hospitalisation as compared to pulmonary function testing six months later when the same HF patients were in a stable phase of their heart failure. Detection of hyperinflation would improve the diagnosis of COPD, and could be performed during hospitalization. Google Scholar
  43. 43.
    Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chronic Obstructive Pulm Dis. 2006;1(4):381–400.Google Scholar
  44. 44.
    US Surgeon General: The health consequences of smoking. Chronic obstructive lung disease. A report of the Surgeon General Rockville, Maryland: US Department of Health and Human Services; Public Health Service; 1984 [], DHHS (PHS) 84–50205. In.; 1984.
  45. 45.
    Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935–9.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.PubMedGoogle Scholar
  47. 47.
    Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMedGoogle Scholar
  48. 48.
    He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002.PubMedGoogle Scholar
  49. 49.
    Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–5. discussion 715–716.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–9.PubMedGoogle Scholar
  51. 51.
    Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(2):119–29.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–9.PubMedGoogle Scholar
  53. 53.
    Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:5s–13.PubMedGoogle Scholar
  54. 54.
    MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258–66. discussion 290–251.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMedGoogle Scholar
  56. 56.
    Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.PubMedGoogle Scholar
  57. 57.
    Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010;7(1):5–10.PubMedGoogle Scholar
  58. 58.
    Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–82.PubMedGoogle Scholar
  59. 59.
    Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28(6):1245–57.PubMedGoogle Scholar
  60. 60.
    Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–91.PubMedGoogle Scholar
  61. 61.
    Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation. 2003;107(11):1460–2.PubMedGoogle Scholar
  62. 62.
    Javed Q, Murtaza I. Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 2013;22(5):323–7.PubMedGoogle Scholar
  63. 63.
    Rutten F: Diagnosis and management of heart failure in COPD. Eureopean Respiratory Monogram 2013.Google Scholar
  64. 64.
    Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Eval Manag Chest. 1991;99(3):715–23.Google Scholar
  65. 65.
    Burghuber O, Bergmann H, Silberbauer K, Hofer R. Right ventricular performance in chronic air flow obstruction. Respiration. 1984;45(2):124–30.PubMedGoogle Scholar
  66. 66.
    Morrison DA, Adcock K, Collins CM, Goldman S, Caldwell JH, Schwarz MI. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol. 1987;9(6):1219–29.PubMedGoogle Scholar
  67. 67.
    Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618–24.PubMedGoogle Scholar
  68. 68.
    Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax. 2003;58(7):556–8.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Mancini GB, Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med. 2005;28(3):118–26.PubMedGoogle Scholar
  70. 70.
    Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003;9(3):142–7.PubMedGoogle Scholar
  71. 71.
    Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest. 2003;124(3):1090–102.PubMedGoogle Scholar
  72. 72.
    Sakamaki F, Satoh T, Nagaya N, Kyotani S, Nakanishi N, Ishida Y. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest. 1999;116(6):1575–81.PubMedGoogle Scholar
  73. 73.
    Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ. 2000;320(7228):167–70.PubMedCentralPubMedGoogle Scholar
  74. 74.
    Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837–49.PubMedGoogle Scholar
  75. 75.
    Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003;123(5):1416–24.PubMedGoogle Scholar
  76. 76.
    Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J Suppl. 2003;46:81s–6.PubMedGoogle Scholar
  77. 77.
    Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11(12):1182–8.PubMedGoogle Scholar
  78. 78.
    Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101(3):353–8.PubMedGoogle Scholar
  79. 79.
    Kwon BJ, Kim DB, Jang SW, Yoo KD, Moon KW, Shim BJ, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010;12(12):1339–44.PubMedGoogle Scholar
  80. 80.
    Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–7.PubMedGoogle Scholar
  81. 81.
    Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.PubMedGoogle Scholar
  83. 83.
    Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795–807.PubMedGoogle Scholar
  84. 84.••
    Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–38. Detailed overview of caveats of betablocker and beta-agonist therapy in patients with COPD and heart failure.PubMedGoogle Scholar
  85. 85.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–7.PubMedGoogle Scholar
  86. 86.
    Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007;9(8):827–33.PubMedGoogle Scholar
  87. 87.
    Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12(6):557–65.PubMedGoogle Scholar
  88. 88.
    Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115–24.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38(3):256–62.PubMedCentralPubMedGoogle Scholar
  90. 90.
    Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J. 2006;27(5):972–9.PubMedGoogle Scholar
  92. 92.
    Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005;26(2):159–64.PubMedGoogle Scholar
  94. 94.
    Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123(6):1964–9.PubMedGoogle Scholar
  95. 95.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.PubMedGoogle Scholar
  96. 96.
    Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571–9.PubMedGoogle Scholar
  97. 97.
    Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2012;9, CD009157.PubMedGoogle Scholar
  98. 98.
    Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.PubMedGoogle Scholar
  99. 99.
    Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–103.PubMedGoogle Scholar
  100. 100.
    Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–85.PubMedGoogle Scholar
  101. 101.
    Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium–the FDA's conclusions. N Engl J Med. 2010;363(12):1097–9.PubMedGoogle Scholar
  102. 102.
    Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. International journal of chronic obstructive pulmonary disease. 2013;8:405–23.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Reid DJ, Carlson AA. Clinical use of aclidinium in patients with COPD. International journal of chronic obstructive pulmonary disease. 2014;9:369–79.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug, healthcare and patient safety. 2013;5:49–55.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Greenberger PA, Cranberg JA, Ganz MA, Hubler GL. A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. The American journal of medicine. 1991;91(1):67–73.PubMedGoogle Scholar
  106. 106.
    Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13–24.PubMedGoogle Scholar
  107. 107.
    White WB, Cooke GE, Kowey PR, Calverley PM, Bredenbroker D, Goehring UM, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758–65.PubMedGoogle Scholar
  108. 108.
    Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3, CD010844.PubMedGoogle Scholar
  109. 109.
    Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29(8):891–905.PubMedGoogle Scholar
  110. 110.
    Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;4, CD008989.PubMedGoogle Scholar
  111. 111.
    Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Comprehensive Heart Failure CenterUniversity of WürzburgWürzburgGermany
  2. 2.Department of Internal Medicine – CardiologyUniversity Hospital WürzburgWürzburgGermany
  3. 3.Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtNetherlands

Personalised recommendations